3/19
05:59 pm
eldn
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results [Yahoo! Finance]
Low
Report
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results [Yahoo! Finance]
3/19
05:10 pm
eldn
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
Low
Report
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
3/16
04:51 pm
eldn
Eledon sees promising data for tegoprubart in islet transplant type 1 diabetes. [Seeking Alpha]
Medium
Report
Eledon sees promising data for tegoprubart in islet transplant type 1 diabetes. [Seeking Alpha]
3/16
01:48 pm
eldn
Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative [Seeking Alpha]
Neutral
Report
Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative [Seeking Alpha]
3/16
07:08 am
eldn
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine [Yahoo! Finance]
Low
Report
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine [Yahoo! Finance]
3/16
07:00 am
eldn
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
Low
Report
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
3/15
02:52 pm
eldn
Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference [Yahoo! Finance]
Low
Report
Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference [Yahoo! Finance]
3/10
07:37 am
eldn
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation [Yahoo! Finance]
Medium
Report
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation [Yahoo! Finance]
3/10
07:06 am
eldn
NewcelX and Eledon partner for NCEL-101 programme [Yahoo! Finance]
Medium
Report
NewcelX and Eledon partner for NCEL-101 programme [Yahoo! Finance]
3/10
07:00 am
eldn
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
Medium
Report
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
3/4
04:05 pm
eldn
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
Medium
Report
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
2/5
04:10 pm
eldn
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
High
Report
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
1/23
07:00 am
eldn
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
Medium
Report
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
1/8
04:56 pm
eldn
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook [Yahoo! Finance]
Low
Report
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook [Yahoo! Finance]
1/8
04:05 pm
eldn
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
Neutral
Report
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
12/31
08:07 am
eldn
The End of Shots? 5 Biotech Stocks Rethinking Diabetes
Neutral
Report
The End of Shots? 5 Biotech Stocks Rethinking Diabetes